This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://localhost/temp/predkladatel/
n16http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/ontology/domain/vavai/
n14http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F05%3A00001075%21RIV09-MSM-11120___/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F05%3A00001075%21RIV09-MSM-11120___
rdf:type
n12:Vysledek skos:Concept
dcterms:description
Cerebrolysin is a compound with neurotrophic and neuroprotective activity. It is produced by enzymatic breakdown of purified brain proteins and consists of low molecular weight peptides and amino acids. Cellular and animal models of cerebral ischaemia have shown that it is a potent neuroprotective agent. We explored the safety and preliminary outcome of Cerebrolysin treatment in patients with acute stroke. Methods. Randomised, placebo-controlled, parallel group trial. Patients with acute stroke were randomised within 24 h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days. Both groups received concomitant treatment with ASA 250 mg/day PO and pentoxifylline 300 mg/day IV. Clinical examinations were performed on days 1, 3, 7, 21 and 90 post baseline. Outcome measures were the Canadian Neurological Scale, the Barthel Index, the Clinical Global Impressions, the Mini-Mental State Examination, and the Syndrome Short Test. Treatment emergent adverse events, lab tests, and vital Cerebrolysin is a compound with neurotrophic and neuroprotective activity. It is produced by enzymatic breakdown of purified brain proteins and consists of low molecular weight peptides and amino acids. Cellular and animal models of cerebral ischaemia have shown that it is a potent neuroprotective agent. We explored the safety and preliminary outcome of Cerebrolysin treatment in patients with acute stroke. Methods. Randomised, placebo-controlled, parallel group trial. Patients with acute stroke were randomised within 24 h of stroke onset to IV therapy with placebo or Cerebrolysin 50 mL/day for 21 days. Both groups received concomitant treatment with ASA 250 mg/day PO and pentoxifylline 300 mg/day IV. Clinical examinations were performed on days 1, 3, 7, 21 and 90 post baseline. Outcome measures were the Canadian Neurological Scale, the Barthel Index, the Clinical Global Impressions, the Mini-Mental State Examination, and the Syndrome Short Test. Treatment emergent adverse events, lab tests, and vital Cerebrolysin je látka s neurotrofickým a neuroprotektivním účinkem. Vyrábí se enzymatickou degradací purifikovaných mozkový proteinů a skládá se z nízkomekulárních peptidů a aminokyselin. Celulární a animální modely mozkové ischemie ukázaly, že má významný neuroprotektivní účinek. Provedli jsme randomizovanou, placebem kontrolovanou studii v níž nemocní s akutním iktem byli randomizováni do 24 hodin na terapii placebem nebo Cerebrolysinem 50 ml/den po dobu 21 dnů. V obou skupinách se podávala též ASA a pentoxyphyllin. Hodnocení provedeno kanadskou neurologickou škálou, indexem Bartelové a CGI. Výsledky: 146 nemocných ve dvou skupinách, pacienti na Cerebrolysinu neměli žádné signifikantní zlepšení proti placebu ve skore CNS, BI a CGI. Signifikantní zlepšeni kognitivních funkcí na Cerebrolysinu bylo pozorováno v Syndrome Short Test. Cerebrolisyn byl dobře tolerován a bezpečný.
dcterms:title
Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial Neuroprotektivní léčba Cerebrolysinem u pacientů s akutním iktem: randomisovaná a kontrolovaná studie Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial
skos:prefLabel
Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trial Neuroprotektivní léčba Cerebrolysinem u pacientů s akutním iktem: randomisovaná a kontrolovaná studie
skos:notation
RIV/00216208:11120/05:00001075!RIV09-MSM-11120___
n4:aktivita
n15:Z
n4:aktivity
Z(MSM0021620816)
n4:cisloPeriodika
3
n4:dodaniDat
n5:2009
n4:domaciTvurceVysledku
n16:1107313
n4:druhVysledku
n18:J
n4:duvernostUdaju
n17:S
n4:entitaPredkladatele
n11:predkladatel
n4:idSjednocenehoVysledku
532582
n4:idVysledku
RIV/00216208:11120/05:00001075
n4:jazykVysledku
n7:eng
n4:klicovaSlova
acute stroke; neuroprotection; clinical trial; stroke therapy; Cerebrolysin
n4:klicoveSlovo
n10:Cerebrolysin n10:stroke%20therapy n10:acute%20stroke n10:clinical%20trial n10:neuroprotection
n4:kodStatuVydavatele
AT - Rakouská republika
n4:kontrolniKodProRIV
[2EE4CCC91C35]
n4:nazevZdroje
Journal of Neural Transmission
n4:obor
n8:FH
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
3
n4:rokUplatneniVysledku
n5:2005
n4:svazekPeriodika
112
n4:tvurceVysledku
Moessler, H. Ladurner, G. Kalvach, Pavel
n4:wos
000227148400006
n4:zamer
n14:MSM0021620816
s:issn
0300-9564
s:numberOfPages
14
n13:organizacniJednotka
11120